Monogenic Disorder: Fabry Disease

  • Lionel Ginsberg


Fabry disease is a rare inborn error of metabolism, which causes a number of neurological disorders including stroke. This chapter summarizes our current understanding of this condition at the molecular level and addresses treatment strategies.


Enzyme Replacement Therapy Fabry Disease Agalsidase Beta Fabry Disease Patient Fabry Outcome Survey 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Desnick RJ, Ioannou YA, Eng CM. α-galactosidase A deficiency: Fabry disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic and molecular bases of inherited disease, vol. 2. 8th ed. New York: McGraw-Hill; 2001. p. 3733–74.Google Scholar
  2. 2.
    Spada M, Pagliardini S, Yasuda M, et al. High incidence of later-onset Fabry disease revealed by newborn screening. Am J Hum Genet. 2006;79:31–40.PubMedCrossRefGoogle Scholar
  3. 3.
    Mehta A, Ricci R, Widmer U, et al. Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry outcome survey. Eur J Clin Invest. 2004;34:236–42.PubMedCrossRefGoogle Scholar
  4. 4.
    Linhart A, Kampmann C, Zamorano JL, et al. Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey. Eur Heart J. 2007;28:1228–35.PubMedCrossRefGoogle Scholar
  5. 5.
    Morgan SH, Rudge P, Smith SJ, et al. The neurological complications of Anderson-Fabry disease (alpha-galactosidase A deficiency) – investigation of symptomatic and presymptomatic patients. Q J Med. 1990;75:491–507.PubMedGoogle Scholar
  6. 6.
    Luciano CA, Russell JW, Banerjee TK, et al. Physiological characterization of neuropathy in Fabry’s disease. Muscle Nerve. 2002;26:622–9.PubMedCrossRefGoogle Scholar
  7. 7.
    Kocen RS, Thomas PK. Peripheral nerve involvement in Fabry’s disease. Arch Neurol. 1970;22:81–8.PubMedCrossRefGoogle Scholar
  8. 8.
    Onishi A, Dyck PJ. Loss of small peripheral sensory neurons in Fabry disease. Histologic and morphometric evaluation of cutaneous nerves, spinal ganglia and posterior columns. Arch Neurol. 1974;31:120–7.PubMedCrossRefGoogle Scholar
  9. 9.
    Mitsias P, Levine SR. Cerebrovascular complications of Fabry’s disease. Ann Neurol. 1996;40:8–17.PubMedCrossRefGoogle Scholar
  10. 10.
    MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet. 2001;38:750–60.PubMedCrossRefGoogle Scholar
  11. 11.
    MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet. 2001;38:769–74.PubMedCrossRefGoogle Scholar
  12. 12.
    Galanos J, Nicholls K, Grigg L, et al. Clinical features of Fabry disease in Australian patients. Intern Med J. 2002;32:575–84.PubMedCrossRefGoogle Scholar
  13. 13.
    Sims K, Politei J, Banikazemi M, et al. Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events. Natural history data from the Fabry Registry. Stroke. 2009;40:788–94.PubMedCrossRefGoogle Scholar
  14. 14.
    Deegan PB, Baehner AF, Barba Romero MA, for the European FOS Investigators, et al. Natural history of Fabry disease in females in the Fabry outcome survey. J Med Genet. 2006;43:347–52.PubMedCrossRefGoogle Scholar
  15. 15.
    Mehta A, Ginsberg L, for the FOS Investigators. Natural history of the cerebrovascular complications of Fabry disease. Acta Paediatr. 2005;94 Suppl 447:24–7.CrossRefGoogle Scholar
  16. 16.
    Ginsberg L, Manara R, Reinke J, et al. Characterisation of ischaemic stroke in Fabry disease: data from the international Fabry outcome survey. Eur J Neurol. 2008;15 Suppl 3:21–2.Google Scholar
  17. 17.
    Fellgiebel A, Müller MJ, Ginsberg L. CNS manifestations of Fabry’s disease. Lancet Neurol. 2006;5:791–5.PubMedCrossRefGoogle Scholar
  18. 18.
    Ginsberg L, Manara R, Valentine AR, et al. Magnetic resonance imaging changes in Fabry disease. Acta Paediatr. 2006;95 Suppl 451:57–62.CrossRefGoogle Scholar
  19. 19.
    Crutchfield KE, Patronas NJ, Dambrosia JM, et al. Quantitative analysis of cerebral vasculopathy in patients with Fabry disease. Neurology. 1998;50:1746–9.PubMedCrossRefGoogle Scholar
  20. 20.
    Fellgiebel A, Müller MJ, Mazanek M, et al. White matter lesion severity in male and female patients with Fabry disease. Neurology. 2005;65:600–2.PubMedCrossRefGoogle Scholar
  21. 21.
    Cabrera-Salazar MA, O’Rourke E, Charria-Ortiz G, et al. Radiological evidence of early cerebral microvascular disease in young children with Fabry disease. J Pediatr. 2005;147:102–5.PubMedCrossRefGoogle Scholar
  22. 22.
    Rolfs A, Böttcher T, Zschiesche M, et al. Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study. Lancet. 2005;366:1794–6.PubMedCrossRefGoogle Scholar
  23. 23.
    Reisin RC, Romero C, Marchesoni C, et al. Brain MRI findings in patients with Fabry disease. J Neurol Sci. 2011;305:41–4.PubMedCrossRefGoogle Scholar
  24. 24.
    Moore DF, Ye F, Schiffmann R, et al. Increased signal intensity in the pulvinar on T1-weighted images: a pathognomonic MR imaging sign of Fabry disease. AJNR Am J Neuroradiol. 2003;24:1096–101.PubMedGoogle Scholar
  25. 25.
    Takanashi J, Barkovich AJ, Dillon WP, et al. T1 Hyperintensity in the pulvinar: key imaging feature for diagnosis of Fabry disease. AJNR Am J Neuroradiol. 2003;24:916–21.PubMedGoogle Scholar
  26. 26.
    Garzuly F, Maródi L, Erdös M, et al. Megadolichobasilar anomaly with thrombosis in a family with Fabry’s disease and a novel mutation in the α-galactosidase A gene. Brain. 2005;128:2078–83.PubMedCrossRefGoogle Scholar
  27. 27.
    Fellgiebel A, Keller I, Marin D, et al. Diagnostic utility of different MRI and MR angiography measures in Fabry disease. Neurology. 2009;72:63–8.PubMedCrossRefGoogle Scholar
  28. 28.
    Ritter M, Dittrich R, Droste DW. Microembolus detection in four patients with Fabry disease: further support for a primarily microangiopathic origin of early cerebrovascular symptoms. Eur Neurol. 2003;50:141–5.PubMedCrossRefGoogle Scholar
  29. 29.
    Moore DF, Scott LT, Gladwin MT, et al. Regional cerebral hyperperfusion and nitric oxide pathway deregulation in Fabry disease: reversal by enzyme replacement therapy. Circulation. 2001;104:1506–12.PubMedCrossRefGoogle Scholar
  30. 30.
    Hilz MJ, Kolodny EH, Brys M, et al. Reduced cerebral blood flow velocity and impaired cerebral autoregulation in patients with Fabry disease. J Neurol. 2004;251:564–70.PubMedCrossRefGoogle Scholar
  31. 31.
    DeGraba T, Azhar S, Dignat-George F, et al. Profile of endothelial and leukocyte activation in Fabry patients. Ann Neurol. 2000;47:229–33.PubMedCrossRefGoogle Scholar
  32. 32.
    Wozniak MA, Kittner SJ, Tuhrim S, et al. Frequency of unrecognized Fabry disease among young European-American and African-American men with first ischemic stroke. Stroke. 2010;41:78–81.PubMedCrossRefGoogle Scholar
  33. 33.
    Baptista MV, Ferreira S, Pinho-E-Melo T, for the PORTuguese Young STROKE Investigators, et al. Mutations of the GLA gene in young patients with stroke: the PORTYSTROKE study–screening genetic conditions in Portuguese young stroke patients. Stroke. 2010;41:431–6.PubMedCrossRefGoogle Scholar
  34. 34.
    Brouns R, Thijs V, Eyskens F, for the BeFaS Investigators, et al. Belgian Fabry study: prevalence of Fabry disease in a cohort of 1000 young patients with cerebrovascular disease. Stroke. 2010;41:863–8.PubMedCrossRefGoogle Scholar
  35. 35.
    Schiffmann R, Kopp JB, Austin 3rd HA, et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA. 2001;285:2743–9.PubMedCrossRefGoogle Scholar
  36. 36.
    Eng CM, Guffon N, Wilcox WR, for the International Collaborative Fabry Disease Study Group, et al. Safety and efficacy of recombinant human α-galactosidase A replacement therapy in Fabry’s disease. N Engl J Med. 2001;345:9–16.PubMedCrossRefGoogle Scholar
  37. 37.
    Schiffmann R, Floeter MK, Dambrosia JM, et al. Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease. Muscle Nerve. 2003;28:703–10.PubMedCrossRefGoogle Scholar
  38. 38.
    Hajioff D, Enever Y, Quiney R, et al. Hearing loss in Fabry disease: the effect of agalsidase alfa replacement therapy. J Inherit Metab Dis. 2003;26:787–94.PubMedCrossRefGoogle Scholar
  39. 39.
    Mehta A, Beck M, Elliott P, for the Fabry Outcome Survey Investigators, et al. Enzyme replacement therapy with agalsidase alfa in patients with Fabry’s disease: an analysis of registry data. Lancet. 2009;374:1986–96.PubMedCrossRefGoogle Scholar
  40. 40.
    Jardim L, Vedolini L, Schwartz IVD, et al. CNS involvement in Fabry disease: clinical and imaging studies before and after 12 months of enzyme replacement therapy. J Inherit Metab Dis. 2004;27:229–40.PubMedCrossRefGoogle Scholar
  41. 41.
    Buechner S, Moretti M, Burlina AP, et al. Central nervous system involvement in Anderson-Fabry disease: a clinical and MRI retrospective study. J Neurol Neurosurg Psychiatry. 2008;79:1249–54.PubMedCrossRefGoogle Scholar
  42. 42.
    Schiffmann R, Rapkiewicz A, Abu-Asab M, et al. Pathological findings in a patient with Fabry disease who died after 2.5 years of enzyme replacement. Virchows Arch. 2005;29:1–7.Google Scholar
  43. 43.
    Altarescu G, Moore DF, Schiffmann R. Effect of genetic modifiers on cerebral lesions in Fabry disease. Neurology. 2005;64:2148–50.PubMedCrossRefGoogle Scholar
  44. 44.
    Albrecht J, Dellani PR, Müller MJ, et al. Voxel based analyses of diffusion tensor imaging in Fabry disease. J Neurol Neurosurg Psychiatry. 2007;78:964–9.PubMedCrossRefGoogle Scholar
  45. 45.
    Hughes DA, Malmenas M, Deegan PB, et al. Fabry international prognostic index – a predictive severity score for Anderson-Fabry disease. J Med Genet. 2012;49:212–20.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London 2013

Authors and Affiliations

  1. 1.University College London, Medical School, Royal Free HospitalLondonUK

Personalised recommendations